Pro-Dex, Inc. (NASDAQ: PDEX) Stock Competitors & Peer Comparison
See PDEX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PDEX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PDEX | $54.93 | +0.48% | 175.4M | 19.34 | $2.84 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
PDEX vs BDX Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BDX's P/E ratio is 11.62. In terms of profitability, PDEX's ROE is +0.29%, compared to BDX's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
PDEX vs BDXA Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BDXA's P/E ratio is 45.70. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, PDEX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
PDEX vs MDLN Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas MDLN's P/E ratio is 45.06. In terms of profitability, PDEX's ROE is +0.29%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, PDEX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
PDEX vs WST Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas WST's P/E ratio is 41.19. In terms of profitability, PDEX's ROE is +0.29%, compared to WST's ROE of +0.19%. Regarding short-term risk, PDEX is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
PDEX vs HOLX Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas HOLX's P/E ratio is 31.54. In terms of profitability, PDEX's ROE is +0.29%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
PDEX vs COO Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas COO's P/E ratio is 15.42. In terms of profitability, PDEX's ROE is +0.29%, compared to COO's ROE of +0.03%. Regarding short-term risk, PDEX is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
PDEX vs BDXB Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BDXB's P/E ratio is 7.60. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
PDEX vs BAX Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BAX's P/E ratio is 10.77. In terms of profitability, PDEX's ROE is +0.29%, compared to BAX's ROE of -0.16%. Regarding short-term risk, PDEX is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
PDEX vs ATR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ATR's P/E ratio is 23.13. In terms of profitability, PDEX's ROE is +0.29%, compared to ATR's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
PDEX vs AVTR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas AVTR's P/E ratio is 13.46. In terms of profitability, PDEX's ROE is +0.29%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, PDEX is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
PDEX vs RGEN Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas RGEN's P/E ratio is 73.31. In terms of profitability, PDEX's ROE is +0.29%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, PDEX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
PDEX vs TFX Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas TFX's P/E ratio is 12.32. In terms of profitability, PDEX's ROE is +0.29%, compared to TFX's ROE of -0.28%. Regarding short-term risk, PDEX is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
PDEX vs BLCO Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BLCO's P/E ratio is 24.88. In terms of profitability, PDEX's ROE is +0.29%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, PDEX is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
PDEX vs STVN Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas STVN's P/E ratio is 31.81. In terms of profitability, PDEX's ROE is +0.29%, compared to STVN's ROE of +0.10%. Regarding short-term risk, PDEX is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
PDEX vs MMSI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas MMSI's P/E ratio is 19.01. In terms of profitability, PDEX's ROE is +0.29%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
PDEX vs ICUI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ICUI's P/E ratio is 19.66. In terms of profitability, PDEX's ROE is +0.29%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, PDEX is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
PDEX vs HAE Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas HAE's P/E ratio is 15.86. In terms of profitability, PDEX's ROE is +0.29%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
PDEX vs XRAY Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas XRAY's P/E ratio is 9.04. In terms of profitability, PDEX's ROE is +0.29%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, PDEX is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
PDEX vs LMAT Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas LMAT's P/E ratio is 37.05. In terms of profitability, PDEX's ROE is +0.29%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, PDEX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
PDEX vs PLSE Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas PLSE's P/E ratio is -27.48. In terms of profitability, PDEX's ROE is +0.29%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, PDEX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
PDEX vs ATRC Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, PDEX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
PDEX vs BLFS Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas BLFS's P/E ratio is -141.85. In terms of profitability, PDEX's ROE is +0.29%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, PDEX is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
PDEX vs AZTA Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas AZTA's P/E ratio is 60.82. In terms of profitability, PDEX's ROE is +0.29%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, PDEX is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
PDEX vs KMTS Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas KMTS's P/E ratio is -8.92. In terms of profitability, PDEX's ROE is +0.29%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, PDEX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
PDEX vs STAA Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas STAA's P/E ratio is 41.02. In terms of profitability, PDEX's ROE is +0.29%, compared to STAA's ROE of -0.06%. Regarding short-term risk, PDEX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
PDEX vs QDEL Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas QDEL's P/E ratio is 11.98. In terms of profitability, PDEX's ROE is +0.29%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, PDEX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
PDEX vs ATRI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ATRI's P/E ratio is 64.50. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, PDEX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
PDEX vs ANGO Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ANGO's P/E ratio is -34.85. In terms of profitability, PDEX's ROE is +0.29%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, PDEX is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
PDEX vs NNNN Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas NNNN's P/E ratio is 145.38. In terms of profitability, PDEX's ROE is +0.29%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, PDEX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
PDEX vs OSUR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas OSUR's P/E ratio is -4.78. In terms of profitability, PDEX's ROE is +0.29%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, PDEX is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
PDEX vs SMTI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas SMTI's P/E ratio is -426.00. In terms of profitability, PDEX's ROE is +0.29%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, PDEX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
PDEX vs UTMD Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas UTMD's P/E ratio is 19.86. In terms of profitability, PDEX's ROE is +0.29%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, PDEX is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PDEX vs INFU Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas INFU's P/E ratio is 23.97. In terms of profitability, PDEX's ROE is +0.29%, compared to INFU's ROE of +0.14%. Regarding short-term risk, PDEX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
PDEX vs KRMD Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas KRMD's P/E ratio is -95.75. In terms of profitability, PDEX's ROE is +0.29%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, PDEX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
PDEX vs MBOT Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas MBOT's P/E ratio is -6.58. In terms of profitability, PDEX's ROE is +0.29%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, PDEX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
PDEX vs AKYA Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas AKYA's P/E ratio is -1.34. In terms of profitability, PDEX's ROE is +0.29%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, PDEX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
PDEX vs STSS Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas STSS's P/E ratio is -0.02. In terms of profitability, PDEX's ROE is +0.29%, compared to STSS's ROE of -1.66%. Regarding short-term risk, PDEX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
PDEX vs DXR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas DXR's P/E ratio is 27.33. In terms of profitability, PDEX's ROE is +0.29%, compared to DXR's ROE of +0.22%. Regarding short-term risk, PDEX is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
PDEX vs OMIC Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas OMIC's P/E ratio is -0.58. In terms of profitability, PDEX's ROE is +0.29%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, PDEX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
PDEX vs IGAP Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas IGAP's P/E ratio is -10.52. In terms of profitability, PDEX's ROE is +0.29%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, PDEX is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
PDEX vs NEPH Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas NEPH's P/E ratio is 50.86. In terms of profitability, PDEX's ROE is +0.29%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, PDEX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
PDEX vs MLSS Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas MLSS's P/E ratio is -6.50. In terms of profitability, PDEX's ROE is +0.29%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, PDEX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
PDEX vs POCI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas POCI's P/E ratio is -6.07. In terms of profitability, PDEX's ROE is +0.29%, compared to POCI's ROE of -0.37%. Regarding short-term risk, PDEX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
PDEX vs SDC Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas SDC's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to SDC's ROE of -1.96%. Regarding short-term risk, PDEX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
PDEX vs HBIO Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas HBIO's P/E ratio is -16.81. In terms of profitability, PDEX's ROE is +0.29%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, PDEX is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
PDEX vs IVC Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas IVC's P/E ratio is -0.79. In terms of profitability, PDEX's ROE is +0.29%, compared to IVC's ROE of -0.46%. Regarding short-term risk, PDEX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
PDEX vs RVP Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas RVP's P/E ratio is -2.06. In terms of profitability, PDEX's ROE is +0.29%, compared to RVP's ROE of -0.08%. Regarding short-term risk, PDEX is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
PDEX vs ZJYL Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, PDEX's ROE is +0.29%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, PDEX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
PDEX vs FEMY Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas FEMY's P/E ratio is -10.25. In terms of profitability, PDEX's ROE is +0.29%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, PDEX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
PDEX vs RGNT Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas RGNT's P/E ratio is -0.08. In terms of profitability, PDEX's ROE is +0.29%, compared to RGNT's ROE of N/A. Regarding short-term risk, PDEX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
PDEX vs NSTG Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas NSTG's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, PDEX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
PDEX vs NXGL Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas NXGL's P/E ratio is -1.13. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, PDEX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
PDEX vs POAI Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas POAI's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to POAI's ROE of -107.05%. Regarding short-term risk, PDEX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
PDEX vs LUCY Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas LUCY's P/E ratio is -0.39. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, PDEX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
PDEX vs MHUA Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas MHUA's P/E ratio is 0.25. In terms of profitability, PDEX's ROE is +0.29%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, PDEX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
PDEX vs NXGLW Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, PDEX is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
PDEX vs GMVD Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas GMVD's P/E ratio is -0.01. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
PDEX vs GMVDW Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas GMVDW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
PDEX vs AVGR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas AVGR's P/E ratio is -0.05. In terms of profitability, PDEX's ROE is +0.29%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, PDEX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
PDEX vs LUCYW Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, PDEX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
PDEX vs GCTK Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas GCTK's P/E ratio is -0.01. In terms of profitability, PDEX's ROE is +0.29%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, PDEX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
PDEX vs APR Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas APR's P/E ratio is 22.59. In terms of profitability, PDEX's ROE is +0.29%, compared to APR's ROE of +9.81%. Regarding short-term risk, PDEX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
PDEX vs IIN Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas IIN's P/E ratio is 226.45. In terms of profitability, PDEX's ROE is +0.29%, compared to IIN's ROE of -0.00%. Regarding short-term risk, PDEX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
PDEX vs ALOG Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ALOG's P/E ratio is 40.93. In terms of profitability, PDEX's ROE is +0.29%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, PDEX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
PDEX vs ATRS Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas ATRS's P/E ratio is 14.95. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, PDEX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
PDEX vs IVTY Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas IVTY's P/E ratio is -3.80. In terms of profitability, PDEX's ROE is +0.29%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, PDEX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
PDEX vs HRC Comparison July 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 175.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, PDEX is priced at $54.93 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 19.34, whereas HRC's P/E ratio is 41.92. In terms of profitability, PDEX's ROE is +0.29%, compared to HRC's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HRC's competition here